The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A08 | Antiobesity preparations, excl. diet products | |
| 3 | A08A | Antiobesity preparations, excl. diet products | |
| 4 | A08AX | Other antiobesity drugs |
| Code | Title | |
|---|---|---|
| A08AX01 | Rimonabant |
| Active Ingredient | Description | |
|---|---|---|
| Rimonabant |
Rimonabant is a selective cannabinoid-1 receptor (CB1) antagonist that inhibits the pharmacological effects of cannabinoid agonists in vitro and in vivo. The endocannabinoid system is a physiological system present in brain and peripheral tissues (including adipocytes) that affects energy balance, glucose and lipid metabolism and body weight, and in neurons of the mesolimbic system modulates the intake of highly palatable, sweet or fatty foods. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ACOMPLIA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
